Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hubei Zhongjia Pharmaceutical is a China-based pharmaceutical manufacturer focused on active pharmaceutical ingredients and generic finished dosage forms. The company is best known as a major producer of albendazole and also manufactures products such as pirenoxine sodium, propyl gallate, tranexamic acid, injections, tablets, capsules, eye drops, nasal drops, ointments, creams, and sprays. It operates from Tianmen, Hubei, with manufacturing activities tied to both Huaqiao Road and Yuekou Industrial Park, and has also referenced a Wuhan marketing function. Available sources indicate the company remains legally active, although recent Chinese business-registry records also show substantial legal and financial enforcement risks. Overall, it appears to be a small commercial-stage Chinese pharma manufacturer with strengths in small-molecule APIs and commodity/generic formulations rather than an innovative clinical biotech pipeline.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hubei Zhongjia Pharmaceutical.